Codebreaker Labs announced the closing of a $4.5 million seed financing led by Kickstart to expand its causal genomics platform and develop its first commercial variant Atlas. The funding will support laboratory scale-up, key scientific hires, and the creation of AI-powered interpretation tools alongside the company’s initial Atlases.
Genomic AI data and the Atlas approach
Codebreaker generates empirical measurements of how individual genetic variants affect human cells, producing data for tens of thousands of variants at a time. The company introduces individual single-nucleotide variants into disease-relevant primary human cells and measures their individual effects at genome scale, producing functional evidence intended to strengthen variant interpretation and train genomic AI models. Each Atlas combines a curated dataset of measured variant effects with AI models trained on that data to support clinical interpretation and biomedical research based on complex genomics assays.
“Genomic AI needs more than DNA sequences. It needs to learn from what genetic changes actually do in human cells,” said Ryan T. Gill, Co-Founder and CEO of Codebreaker Labs.
Funding, partners and pipeline
The round included continued investment from existing backers Buff Gold Ventures and Children’s Hospital Colorado, and new participation from Denver Ventures, Service Provider Capital, and Pelican Trust, an affiliate of Codebreaker Chairman Sandy Zweifach. Dalton Wright, General Partner at Kickstart, said: “As genomic AI advances, high-quality experimental data will become an increasingly valuable asset.”
Codebreaker is building its first Atlas through an expanding collaboration with a leading children’s hospital. The company’s initial work focuses on immunology and blood cancers, with a first commercial Atlas targeted for 2027. That first Atlas is designed to measure the effects of 100,000 genomic variants, providing deep coverage for the chosen indication.
Academic medical centers, hospitals, genomics institutes, biopharma and frontier AI companies interested in collaborating with Codebreaker to develop causal genomics data and AI applications can contact hello@codebreakerlabs.io.
